tokens: Primary efficacy end points were reduction in clinical systolic BP ( SBP )/ diastolic BP ( DBP ) from baseline to study end and number of responders ( ie , patients who achieved target SBP / DBP < 130 /< 80 mm Hg ) at end of study .